Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 11061 clinical trials
A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS CMML or AML

Study ASTX030-01 is designed to move efficiently from Phase 1 to Phase 3. Phase 1 consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at escalating dose levels of oral cedazuridine and azacitidine (only one study drug will be escalated at a time) followed by a Dose …

graft versus host disease
major surgery
chronic myeloid leukemia
acute leukemia
immunosuppressive agents
  • 0 views
  • 19 Feb, 2024
  • 2 locations
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

This is a Phase I dose-finding study of FT596 as monotherapy and in combination with Rituximab or Obinutuzumab in subjects with relapsed/refractory B-cell Lymphoma or Chronic Lymphocytic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

rituximab fludarabine
treatment regimen
rituximab
b-cell lymphoma refractory
refractory b-cell non-hodgkin lymphoma
  • 0 views
  • 19 Feb, 2024
  • 3 locations
Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients

The purpose of this study is to evaluate the efficacy and safety of decitabine combined with HAAG regimen in the treatment of newly diagnosed patients with ETP-ALL/LBL, T/M-MPAL and ALL/LBL with myeloid or stem cell markers.

  • 0 views
  • 19 Feb, 2024
  • 1 location
TPM Regimen (Thalidomide Prednisone and Methotrexate) in LGLL

Large granular lymphocytic leukemia (LGLL) is a lymphoproliferative disease, with LGL infiltration in peripheral blood and bone marrow, hepatosplenomegaly, and cytopenia.

lymphoproliferative disorder
prednisone
hepatosplenomegaly
leukemia
t-cell large granular lymphocytic leukemia
  • 0 views
  • 19 Feb, 2024
  • 9 locations
CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies

In this protocol, the investigators hypothesize that modifying the process of producing CAR+ T-cells can help to improve responses and reduce toxicities. Building on previous in vitro studies that have shown successful production of CAR+ T-cells using a new production approach, the investigators are now studying the ability to produce …

graft versus host disease
measurable disease
ejection fraction
blood transfusion
systemic disease
  • 0 views
  • 19 Feb, 2024
  • 1 location
Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

This phase II trial studies how well decitabine with ruxolitinib or fedratinib works before hematopoietic stem cell transplant in treating patients with accelerated/blast phase myeloproliferative neoplasms (tumors). Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, …

thrombocytosis
hydroxyurea
blood count
hyperleukocytosis
polycythemia vera
  • 0 views
  • 19 Feb, 2024
  • 1 location
Brief Title: Study of BGB-10188 as Monotherapy and in Combination With Zanubrutinib and Tislelizumab

The purpose of this study is to determine the maximum tolerated dose (MTD), recommended Phase 2 dose(RP2D),safety & tolerability of BGB-10188: as monotherapy in participants with mature B-cell malignancies; oin combination with zanubrutinib in participants with relapse/refractory follicular lymphoma (R/R FL), mantle cell lymphoma (MCL) or diffuse large B-cell lymphoma …

MRI
refractory follicular lymphoma
solid tumor
metastatic melanoma
esophageal cancer
  • 0 views
  • 19 Feb, 2024
  • 4 locations
A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies

A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies.

  • 0 views
  • 19 Feb, 2024
  • 1 location
Ibrutinib + Venetoclax in Untreated WM

This study evaluates the safety and efficacy of Ibrutinib combined with Venetoclax (IVEN) in the treatment of adults diagnosed with Waldenstrom's macroglobulinemia (WM) cancer with a specific MYD88 gene mutation. This research study involves an experimental drug combination of targeted therapies. The names of the study drugs involved in this …

waldenstrom's macroglobulinemia
venetoclax
bone marrow biopsy
absolute neutrophil count
measurable disease
  • 0 views
  • 19 Feb, 2024
  • 2 locations
Molecular Diagnostic Platform for AML

This will be a translational study without any therapeutic intervention, for the purpose of analyzing the diagnostic and molecular results / characterization of adult patients with AML, regardless of the treatment they receive. Newly diagnosed or relapsed/resistant AML patients will be included.

  • 0 views
  • 19 Feb, 2024
  • 7 locations